Skip to content

Neurophysiological correlates of ketamine-induced dissociative state in bipolar disorder: insights from real-world clinical settings.

Claudio Agnorelli, Alessandra Cinti, Giovanni Barillà, Francesco Lomi, Adriano Scoccia, Alberto Benelli, Francesco Neri, Carmelo Luca Smeralda, Alessandro Cuomo, Emiliano Santarnecchi, Elisa Tatti, Kate Godfrey, Francesca Tarantino, Andrea Fagiolini, Simone Rossi

Molecular psychiatry January 14, 2025 DOI: 10.1038/s41380-025-02889-2 via PubMed

Summary

AI-generated from the abstract

In patients with bipolar disorder and treatment-resistant depression, a subanesthetic dose of ketamine alters brain activity patterns measured by EEG. Ketamine reduced low-frequency power and increased gamma oscillatory power, flattened the slope of power spectra, and increased brain signal entropy, especially in high-frequency bands. Patients who responded later to treatment showed greater EEG changes than early responders, suggesting underlying differences in treatment sensitivity. These neurophysiological effects may help explain ketamine's therapeutic mechanisms and could guide personalized treatment for mood disorders.

Study at a glance

Characteristics Observational cohort Peer reviewed
Sample size 30
Population Bipolar disorder inpatients with treatment-resistant depression
Intervention Ketamine
Dose 0.5 to 1 mg/kg
Topics Ketamine
Keywords Depression treatment Neuroscience Brain activity Mental health
Citations 8
Key finding Ketamine reduced low-frequency spectral power, increased gamma oscillatory power, flattened power spectra slopes, and increased brain signal entropy, with later responders showing greater EEG changes than early responders.

Abstract

Ketamine, a dissociative compound, shows promise in treating mood disorders, including treatment-resistant depression (TRD) and bipolar disorder (BD). Despite its therapeutic potential, the neurophysiological mechanisms underlying ketamine's effects are not fully understood. This study explored acute neurophysiological changes induced by subanesthetic doses of ketamine in BD patients with depression using electroencephalography (EEG) biomarkers. A cohort of 30 BD (F = 12) inpatients with TRD undergoing ketamine treatment was included in the study. EEG recordings were performed during one of the ketamine infusions with doses ranging from 0.5 to 1 mg/kg, and subjective effects were evaluated using the Clinician-Administered Dissociative States Scale (CADSS). Both rhythmic and arrhythmic features were extrapolated from the EEG signal. Patients who exhibited a clinical response to ketamine treatment within one week were classified as early responders (ER), whereas those who responded later were categorized as late responders (LR). Ketamine reduced low-frequency spectral power density while increasing gamma oscillatory power. Additionally, ketamine flattened the slope of the power spectra, indicating altered scale-free dynamics. Ketamine also increased brain signal entropy, particularly in high-frequency bands. Notably, LR exhibited greater EEG changes compared to ER, suggesting endophenotypic differences in treatment sensitivity. These findings provide valuable insights into the neurophysiological effects of ketamine in BD depression, highlighting the utility of EEG biomarkers for assessing ketamine's therapeutic mechanisms in real-world clinical settings. Understanding the neural correlates of ketamine response may contribute to personalized treatment approaches and improved management of mood disorders.

Explore topics

Comments

No comments yet.

Log in to comment